Since this study focuses on a specific clinical trial, namely on combination therapy for 18 breast tumor individuals using tremelimumab and durvalumab, the parameters, including the quantity of tumour-draining lymph nodes, tumour growth rate, checkpoint manifestation and malignancy cell diameter, are estimated to be metastatic breast cancer-specific [20]
Since this study focuses on a specific clinical trial, namely on combination therapy for 18 breast tumor individuals using tremelimumab and durvalumab, the parameters, including the quantity of tumour-draining lymph…